Müeloomtõbi Diagnoosimis- ja ravijuhis
14) Tricot G. Treatment advances in multiple myeloma, British Journal of
Haematology, 125, 24-30.
-43-
15) Barlogie B, Desican R, Eddelmon P. Extended survival in advanced and refractory
multiple myeloma after single-agent thalidomide: identification of prognostic
factors in a phase 2 study of 169 patients, Blood (2001) 98: 492-494.
16) Heinz L et al. Management of disease-related anemia in patients with multiple
myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations,
the Hematology Journal (2002) 3: 121-130
17) Richardson P et al. A phase 2 study of bortezomib in relapsed, refractory
myeloma, N Engl J Med (2003) 348: 2609-17
18) Jagannath s. et al. A phase 2 study of two doses of bortezomib in relapsed or
refractory myeloma, British Journal of Haematology (2004) 127: 165-172
19) Harousseau J-L. Bortezomib in multiple myeloma: treatment approach and
outcomes, EJC Supplements (2004) vol 2
annaabi.ee 
